The European Medicines Agency (EMA) has published advice from its advisory groups set up to provide guidance on the drafting of policy for access to clinical trial data. The agency has come under increasing pressure in recent years from, on the one hand, publishers, patients and medical advocates seeking greater access to clinical data on experimental drugs and, commercial entities, on the other hand, seeking to protect what is argued to be commercially sensitive and potentially confidential information.